# US 2017/0283772 A1 · Methods for differentiation of human pluripotent stem cells to brain microvascular endothelial cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283772 A1
- Document ID: US20170283772A1
- Status: Published application
- Kind: A1
- Application number: 15/478,463
- Filed: 2017-04-04
- Published: 2017-10-05
- Earliest claimed: 2016-04-05
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Tongcheng Qian; Eric V. Shusta; Sean P. Palecek
- Web page: https://patentgrep.com/patent/US20170283772A1

## CPC

- C12N 5/069: {Vascular Endothelial cells}
- C12N 2500/38: Vitamins
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods for generating functional brain microvascular endothelial cells (BMECs) under chemically defined, serum-free conditions are provided. In particular, efficient and cost-effective methods for generating functional BMECs under chemically defined culture conditions are provided. BMECs obtained according to the methods provided herein are suitable for in vitro blood brain barrier (BBB) formation.

## Claims

### Claim 1

A method for generating a population of human brain microvascular endothelial cells (BMECs) from human pluripotent stem cells, wherein the method comprises, in order,
(a) culturing human pluripotent stem cells for about 24 hours in a chemically defined, serum-free culture medium that comprises an activator of Wnt/β-catenin signaling, whereby cells that express mesodermal markers are obtained;
(b) culturing the cells expressing mesodermal markers for about 5 days in the presence of a chemically defined, serum-free culture medium comprising B27 supplement, whereby cells that express endothelial progenitor marker Flk-1 are obtained; and
(c) culturing the Flk-1+ cells of (b) for about two days in the presence of a chemically defined, serum-free endothelial medium comprising B27 supplement, bFGF/FGF2, and retinoic acid (RA), whereby a cell population comprising human BMECs is obtained.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human pluripotent stem cells of (a) are cultured in a chemically defined, serum-free culture medium at a cell density of about 35×103 cells/cm2 for about 3 days prior to exposure to the chemically defined, serum-free culture medium comprising an activator of Wnt/β-catenin signaling.

### Claim 3 (depends on 1)

The method of claim 1, wherein at least 95% of cells of the cell population of (c) are BMECs cells positive for expression of one or more of CD31, p-glycoprotein (Pgp), occludin, and claudin-5.

### Claim 4 (depends on 1)

The method of claim 1, further comprising growing the human BMECs of step (c) as a monolayer to confluence.

### Claim 5 (depends on 4)

The method of claim 4, comprising the step of taking an initial transendothelial electrical resistance (TEER) measurement of the confluent monolayer, wherein the TEER measurement is greater than 2000 Ohm (Ω)×cm2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the activator of Wnt/β-catenin signaling is a Gsk3 inhibitor.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Gsk3 inhibitor is a small molecule selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.

### Claim 8 (depends on 6)

The method of claim 6, wherein the Gsk3 inhibitor is CHIR99021 and is present in a concentration of about 3 μM to about 12 μM.

### Claim 9 (depends on 1)

The method of claim 1, wherein no cell separation or selection step is used to obtain the cell population comprising BMECs.

### Claim 10 (depends on 1)

A human BMEC cell population produced by the method of claim 1.
